What's the worst company of 2020?

Tell us which company disappointed you this year.

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

10.59+0.32 (+3.12%)

As of 11:39AM EST. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	10.27
Open	10.30
Bid	10.62 x 1200
Ask	10.67 x 1000
Day's Range	9.88 - 10.67
52 Week Range	4.71 - 19.47
Volume	230,483
Avg. Volume	347,155

Market Cap	143.881M
Beta (5Y Monthly)	1.18
PE Ratio (TTM)	N/A
EPS (TTM)	-2.14
Earnings Date	Jun 29, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	38.75

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium's CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia ("R/R AML"). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to working on Actimab-A development, Dr. Chen will also utilize her training in immunology and experience in translational medicine to identify areas of synergy between targeted radiotherapy with Actimab-A and other therapeutic modalities.
- ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia
  Business Wire
- $Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma$
  Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
  GlobeNewswire
PR Newswire
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab and the radioisotope iodine-131 used in the Company's lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs. Actinium owns issued or pending patents within the United States and globally covering composition of matter, formulation, methods of use, and methods of administration with potential coverage for 19 years or longer. Importantly, Actinium owns an issued patent in the US covering composition of matter, for which the Company expects validity until 2037. In addition, the Company owns a second issued US patent that further covers composition of matter, methods of use, and methods of administration for Iomab-B. The company has also received a notice of allowance in Europe for this second patent and expects it to be in force until 2036.
Zacks
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.16, marking a -1.06% move from the previous day.